Agomab Names David Epstein as Board Chairman

Agomab Therapeutics NV has announced the appointment of David Epstein as non-executive board member and Chairman of its Board of Directors. David Epstein is a seasoned industry leader, having most recently served as the CEO of Seagen and a member of its Board of Directors. During his tenure at Seagen, the company experienced significant growth in its portfolio of cancer treatments and was acquired by Pfizer for over $43 billion in December 2023. Epstein also previously served as the CEO of Novartis Pharmaceuticals, bringing over 30 years of drug development, commercialization, and leadership experience on a global scale. His career includes the development and commercialization of more than 30 new molecular entities, such as Glivec, Tasigna, Gilenya, Cosentyx, Entresto, and Padcev. He has been recognized by FierceBiotech as one of the "25 most influential people in biopharma."

Tim Knotnerus, CEO of Agomab, expressed his enthusiasm about Epstein's appointment, stating, "We are very happy to welcome David as Chairman of our Board of Directors. David serves as a role model in the industry, and we look forward to working closely with him and leveraging his experience to help bring innovative treatments to patients with fibrotic diseases." Knotnerus also extended his gratitude to John Haurum for his dedication and leadership as the previous Chair, noting Haurum’s contributions during a transformational period for the company, which included multiple successful financing rounds, the acquisition of Origo Biopharma, and the transition from a preclinical to a clinical-stage company.

David Epstein, in his new role as Chairman, shared his optimism about Agomab’s potential, saying, "I am very impressed by Agomab’s science and strategy and I look forward to working with Tim and his team in bringing Agomab to the next phase of development and growth. Fibrotic diseases represent a serious unmet medical need, and I truly believe Agomab’s approach could represent great strides for patients with Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis, if approved."

Agomab Therapeutics is dedicated to achieving disease modification by modulating fibrosis and regeneration in chronic conditions like Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis. The company’s approach targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, and employs specialized capabilities in organ-restricted small molecules and high-affinity antibodies. With a distinct clinical pipeline addressing multiple fibrotic disorders, comprehensive research and development capabilities, a solid business development track record, and robust investor support, Agomab is positioning itself as a leading biopharmaceutical company.